Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines

This publication has 19 references indexed in Scilit:

• Nuclear Factor-κB is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma
  Cancer Research, 2004
• NF-κB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach
  Seminars in Cancer Biology, 2002
• Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaBalpha: correlation with induction of cyclooxygenase-2
  Carcinogenesis: Integrative Cancer Research, 2002
• Cyclooxygenase‐2: A novel molecular target for the prevention and treatment of head and neck cancer
  Head & Neck, 2002
• Inhibition of Tumor Necrosis Factor-α-induced Nuclear Translocation and Activation of NF-κB by Dehydroxymethylepoxyquinomicin
  Published by Elsevier ,2002
• The Roles of JNK1 and Stat3 in the Response of Head and Neck Cancer Cell Lines to Combined Treatment with All trans‐retinoic Acid and 5‐Fluorouracil
  Japanese Journal of Cancer Research, 2002
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
  Journal of Clinical Investigation, 2001
• Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells
  Proceedings of the National Academy of Sciences, 2000
• Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C
  Bioorganic & Medicinal Chemistry Letters, 2000
• Epidermal growth factor activation of NF-κB is mediated through IκBα degradation and intracellular free calcium
  Oncogene, 1998